The purpose of the study is to compare pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and the preservation of autonomy (score IADL).
Colorectal cancer is one of the most frequent cancers diagnosed in France. The average age of diagnosis in 2012 was 70 years old for men and 73 years for women, confirming that colorectal cancer is a disease of the elderly population. The literature concerning combined treatments of colorectal cancer in the elderly is extremely limited. The application of combined treatments in the geriatric population is associated with an increase in the therapeutic complications. These post-operative complications together with the comorbidities and age are unfavorable prognostic factors for survival in patients with cancer of the rectum; this explains why the improved results obtained during the last decades are perceptible in younger patients and not in the elderly. In the general population, pre-operative radio-chemotherapy has imposed itself as a standard treatment for the cancer of the rectum locally advanced. The utilization of fluoropyrimidines associated with radiotherapy (RT) delivered in fractions \[long course RT (50 Gy in 5 weeks), surgery planned 6 to 8 weeks later\] increases the complete histological response rate and decreases significantly the rate of local relapse. The short-course RT \[short course RT using the Swedish model (5x5 Gy in 5 days), with the surgery programmed the following week\] is the standard neoadjuvant protocol in an important number of countries and/or academic groups. The studies that have compared the fractioned RT scheme to the short-course RT protocols have not shown any evidence of a change in efficacy of the short course RT concerning the following criteria: rate of R0 resection, rate of sphincter conservation, rate of relapse at 3 years, the disease free survival or the overall survival. Similarly, there appears to be no difference in severe toxicities in the long term. It should however be noted that short-course RT followed by immediate surgery may be less efficient than combined treatment in patients with a distal T3 cancer, even though these conclusions published by Ngan have been criticized by certain. On the other hand, the fractioned combined treatments results in more tumor and stage reduction and thus more sterilization. Nevertheless a retrospective analysis, performed in the Stockholm region, in patients irradiated with short-course protocol but operated with a delay of at least 4 weeks resulted in a sterilization rate of 8%. This result is even more interesting since in this cohort, 46% of the patients had a tumor classified T4 and that 38% of the patients had a primitive tumor considered inoperable. In the elderly population, the neoadjuvant treatment has rarely been studied. An exploratory analysis of the PRODIGE 2 study, based on age as the criteria, has shown that pre-operative radio-chemotherapy is significantly more toxic in the elderly population, from 70 years of age. Globally the lower tolerance for the pre-operative radio-chemotherapy results in more frequent early termination of RT and a statistically significant decrease in the number of patients operated. Furthermore, if the type of surgery was not significantly different between patients \<70 years and those ≥70 years, we observe a non-significant increase in the rate of prolonged stoma (patients amputated without closure of the stoma). These differences in the surgical procedures is also observed in other publications, placing the emphasis on the fact that in the absence of any difference in the clinical presentation or the characteristic of the tumor, the risk of real or supposed decompensation modifies the surgical care. These data, as well as those in the literature, provides evidence that the pre-operative radio-chemotherapy strategy followed by surgery, the standard strategy in younger patients, is associated with more side effects in the elderly, resulting in the benefit-risk balance, in this population, to be more questionable. It is therefore necessary to conduct a specific studies in the elderly population, with cancer of the rectum with the objective to maintain the carcinological results obtained with classical radio-chemotherapy with at the same time better controlling the secondary effects of the treatment and the risk of decompensation of the patients: the short course radiotherapy associated with a delayed surgery may be a therapeutic scheme well adapted to this population. The investigators therefore propose a study comparing pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and the preservation of autonomy (score IADL).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
103
radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
R0 resection rate
Compare the efficacy between the arm A and the arm B (with an objective of non-inferiority)
Time frame: 3 months
IADL (Instrumental Activities of Daily Living) Score
Compare the maintenance of autonomy between the arm A and arm B (with an objective of superiority)
Time frame: 1 year
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.03
Description of the Adverse Events during the pre-operative period.
Time frame: 3 months
Post-operative complications
according to Dindo-Clavien classification
Time frame: 3 months
Death rate
Death rate is defined as the percentage of patients who died since the date of randomisation at 6 and 12 months post-surgery (M6 and M12) from any cause
Time frame: at 6 and 12 months
Overall survival (OS)
The OS is defined as the interval between the date of randomization and the date of deaths from any cause
Time frame: 10 years
Specific survival
The specific survival is defined as the interval between the date of randomization and the date of deaths due to cancer.
Time frame: 10 years
Disease free survival
The disease free survival is defined as the interval between the date of randomization and the date of cancer relapse (local regional or distant), second cancer or death from any cause.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre Hospitalier d'Abbeville
Abbeville, France
Clinique Claude Bernard
Albi, France
CHU Amiens Picardie
Amiens, France
Polyclinique Maymard
Bastia, France
Centre Hospitalier de Beauvais
Beauvais, France
CHU de Besançon
Besançon, France
Cebtre Hospitalier de Blois
Blois, France
Hôpital Avicenne
Bobigny, France
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
...and 27 more locations
Time frame: 10 years
Loco-regional disease free survival
The disease free survival is defined as the interval between the date of randomization and the date of cancer relapse (local or regional).
Time frame: 10 years
Rate of stoma
percentage of patients with definitive or transitional stoma after surgery.
Time frame: at 6 and 12 months
Instrumental Activities of Daily Living (IADL)
Autonomy Assessment
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Activities of Daily Living (ADL)
Autonomy Assessment
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Questionnaire G8
Geriatric Screening
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Mini-Mental Score Examination (MMSE)
Cognitive functioning
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Walking gate
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Geriatric Depression Scale (GDS15)
Depression Assessment
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Charlson score
Comorbidities evaluation
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
Mini Nutritional Assessment (MNA)
Nutritional Evaluation
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery
EORTC QLQ-C30 + EDL14
Quality of Life (QLQ)
Time frame: Baseline, within 2 weeks before surgery and 3, 6 and 12 months after surgery